Rise of Weight Loss Drugs Prompts New 1Q Panel

US-based consumer insights company 1Q has launched a prescription-verified panel of users of GLP-1 drugs, including weight loss medications like Ozempic and Wegovy.

GLP-1 drugs are so -called because they mimick the action of the glucagon-like peptide-1 hormone, in order to treat type 2 diabetes or to help patients lose weight.

1Q, whose platform promises a '100% human member base and zero survey fraud', allows its clients to create customised, proprietary consumer panels 'within minutes'. The company uses a proprietary, permission-based insights panel of more than 1 million double-opted-in US members, and says it never works with third-party panel aggregators or exchanges. Respondents answer in real time, by mobile, and are paid instantly, per response, in cash, directly to their PayPal account or to a charity of their choice.

The firm says it created a prescription-verified panel of 1,000 GLP-1 drug users in a single day, in response to growing demand from clients seeking to understand the rising popularity of GLP-1s and their effect on business. In addition to a panel of 300 people using GLP-1 for diabetes and 700 for weight loss, the firm also recruited 1,400 lapsed users and another 9,400 people 'open to trying' the drugs.

Current users are verified through a prescription review using the platform's photo-response capability, and the panel is now available to all 1Q customers.

Founder and CEO Keith Rinzler (pictured) comments: 'The GLP-1 panel is just one of thousands of custom panels that have been created on the 1Q platform. Thanks to our Radically Simple interface and more than 1 million guaranteed human members who are ready to engage, our customers are creating custom panels every day.'

Web site: www.1q.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.